Selected article for: "parainfluenza virus and RSV respiratory syncytial virus"

Author: Liu, Margaret A.
Title: A Comparison of Plasmid DNA and mRNA as Vaccine Technologies
  • Document date: 2019_4_24
  • ID: 0fx1b7ph_75
    Snippet: Concomitant administration of other drugs may impact mRNA metabolism and thus may decrease potency of mRNA vaccine Reported Phase I clinical trial results for mRNA vaccines are encouraging, although only the results of the first rabies mRNA vaccine have been published in the peer reviewed literature. The results for the human Metapneumovirus + Parainfluenza virus 3, and the Respiratory syncytial virus (RSV) phase I studies were announced via pres.....
    Document: Concomitant administration of other drugs may impact mRNA metabolism and thus may decrease potency of mRNA vaccine Reported Phase I clinical trial results for mRNA vaccines are encouraging, although only the results of the first rabies mRNA vaccine have been published in the peer reviewed literature. The results for the human Metapneumovirus + Parainfluenza virus 3, and the Respiratory syncytial virus (RSV) phase I studies were announced via press release, thus details are not available. The target for the RSV vaccine mRNA was not publicly disclosed at the time the Phase I study was initiated, and to this date, the study appears to not be listed on clinicaltrials.gov. Whether the immune responses are at sufficient levels or have the types of needed immune responses and the necessary duration to result in protective efficacy is unknown and is not necessarily predicted by the Phase I studies.

    Search related documents:
    Co phrase search for related documents